Semaglutide is a GLP-1 receptor agonist that has reshaped metabolic research over the past several years. Originally developed for type 2 diabetes, its effects on weight regulation — demonstrated in the STEP clinical trial program — have made it one of the most studied compounds in metabolic science.

The GLP-1 Mechanism

GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the gut after eating. It signals through three main pathways:

  • Pancreas: Stimulates glucose-dependent insulin secretion and suppresses glucagon release — regulating blood sugar without causing hypoglycemia.
  • Stomach: Slows gastric emptying, prolonging the sensation of fullness after meals.
  • Brain: Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce appetite and food intake.

What makes Semaglutide notable is its extended half-life (~7 days) — achieved through structural modifications that resist enzymatic degradation — making once-weekly research protocols feasible compared to earlier GLP-1 agonists requiring daily administration.

Key Clinical Findings (STEP Trials)

The STEP (Semaglutide Treatment Effect in People with Obesity) program produced some of the most striking weight loss data in metabolic research:

  • STEP-1 (Wilding et al., 2021): 1,961 participants. Mean body weight reduction of 14.9% with Semaglutide 2.4mg vs 2.4% with placebo at 68 weeks.
  • STEP-5 (Garvey et al., 2022): 304 participants. Sustained weight loss of 15.2% over 104 weeks — demonstrating durability of effect.
  • SELECT (Lincoff et al., 2023): 17,604 participants with established CVD. Semaglutide reduced major adverse cardiovascular events by 20% independent of weight loss.

What Researchers Should Know About Sourcing

  • Semaglutide is one of the most expensive peptides to synthesize due to its large molecular weight (4,114 Da) and complex acylation step.
  • LC-MS identity confirmation is critical — some counterfeit products substitute cheaper GLP-1 agonists with shorter half-lives.
  • Novo Nordisk's patent enforcement is aggressive in certain jurisdictions. Researcher-use labeling is essential.

For research use only. Not for human consumption.